JGC
ONCT

J. Goldman & Co’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

J. Goldman & Co’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,181
Closed -$587K – 497
2021
Q2 		$587K Buy
6,181
+2,878
+87% +$342K 0.02% 317
2021
Q1 		$550K Sell
3,303
-3,049
-48% -$403K 0.02% 353
2020
Q4 		$623K Buy
+6,352
New +$402K 0.03% 268

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

J. Goldman & Co's ONCT Position: Q3 2021 in Review

J. Goldman & Co sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2021, closing a stake of 6,181 shares — an estimated $587K sold.

J. Goldman & Co first reported a position in ONCT in Q4 2020 and held it in 3 quarters. The position peaked at $623K in Q4 2020. 76 funds tracked by Wall St. Rank hold ONCT as of Q3 2021.

  • J. Goldman & Co reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • J. Goldman & Co sold 6,181 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $587K.
  • J. Goldman & Co first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • J. Goldman & Co's Oncternal Therapeutics, Inc. Common Stock position peaked at $623K in Q4 2020.
  • 76 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2021.

Based on J. Goldman & Co's 13F filing for Q3 2021, filed 15 Nov 2021.